A5070818915- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Diagnosis and treatment of tuberculosis
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Artificial Intelligence in Healthcare and Education
- Sarcoma Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
- Renal cell carcinoma treatment
- Computational Physics and Python Applications
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- Hematological disorders and diagnostics
- Blood Coagulation and Thrombosis Mechanisms
- Cutaneous lymphoproliferative disorders research
- Hemophilia Treatment and Research
- Cutaneous Melanoma Detection and Management
University of Pittsburgh Medical Center
2022-2025
University of Iowa
2020-2025
University of Pittsburgh
2023-2025
UPMC Hillman Cancer Center
2024
University of Iowa Hospitals and Clinics
2019-2022
Wayne State University
2022
St. Vincent's University Hospital
2022
Icahn School of Medicine at Mount Sinai
2022
Jackson Memorial Hospital
2022
University of Miami
2022
Abstract Background CD8+ tumor-infiltrating lymphocyte (TIL) predicts response to anti-PD-(L)1 therapy. However, there remains no standardized method assess TIL in melanoma, and developing a specific, cost-effective, reproducible, clinically actionable biomarker elusive. We report on the development of automatic density quantification via whole slide image (WSI) analysis advanced melanoma patients treated with front-line anti-PD-1 blockade, correlation immunotherapy response. Methods...
Histologic grade is a key predictor for pseudomyxoma peritonei (PMP) of appendiceal origin that used to guide clinical management. However, some tumors demonstrate disease behavior deviates from their histologic grade. A recent study suggested TP53, GNAS , and RAS mutation analysis could stratify into distinct molecular groups with different prognosis. We investigated alterations in 114 patients PMP who were uniformly treated cytoreductive surgery intraperitoneal chemotherapy (CRS+IPCT)....
Abstract The intestinal microbiome contributes to colorectal carcinogenesis, disease progression, and response therapy. Pathologic complete is the therapeutic goal of neoadjuvant chemoradiation in rectal carcinoma. Nonoperative management has become an accepted strategy, markers treatment are needed. Intestinal commensal bacteria contribute radiation colitis, microbiome-targeted therapies have shown promise clinical trials. We investigated relationship between mucosa-associated bacteria,...
<p>Mucosal microbiome β diversity is altered by neoadjuvant therapy and reflects colitis symptoms. Mucosa-associated bacteria were profiled using 16S rDNA sequencing from FFPE. <b>A,</b> α did not differ among the treatment groups several indices including Faith PD. <b>B,</b> Significant differences detected with PERMANOVA test, although clear separation of easily visualized unweighted UniFrac principal component analysis (PCoA). n.s., significant.</p>
<p>Mucosal microbiome α diversity is decreased with high radiation injury histology score. Radiation scoring was performed by three independent observers according to a previously published scheme (<a href="#bib36" target="_blank">36</a>). <b>A,</b> Representative hematoxylin and eosin–stained slide shows submucosal fibrosis thickened blood vessels (arrows) in rectum specimen following neoadjuvant radiation. <b>B,</b> Modest correlation treatment...
<p>Predicted metabolic pathways associated with host radiation responses are enriched in complete pathologic responder microbiomes<i>.</i> Metabolic pathway gene quantities were predicted from 16S rDNA sequence data using PICRUSt2, and enrichment testing was done by LDA (<b>A</b>, LEfSe; refs. <a href="#bib42" target="_blank">42</a>, href="#bib43" target="_blank">43</a>). Predicted NAD salvage biosynthesis (<b>B</b>),...
<p>Microbiome β diversity distinguishes complete and incomplete pathologic neoadjuvant treatment response. Only the 40 patients treated with chemoradiation were included in this analysis. <b>A,</b> Representative hematoxylin eosin–stained slide from a rectum resection after shows effect fibrosis hemosiderin pigment, rare small groups of residual carcinoma cells corresponding to response score 1 (arrow). <b>B,</b> Unweighted UniFrac distances significantly...
<p>Table S1</p>
<p>Taxa differ by neoadjuvant treatment modality and radiation colitis. <b>A,</b> Phylum-level abundances were related to the group as detected with Kruskal–Wallis tests. <b>B,</b> Specific taxa identified differentially abundant across all groups LEfSe (<a href="#bib42" target="_blank">42</a>), using a default LDA effect score cutoff of 3.0. <b>C–E,</b> Relative high size are plotted. <i>Bacillaceae</i> higher in patients...
<p>Table S2</p>
<p>Study group demographics, stage, and oncologic treatment exposures</p>
<p>Figure S1</p>
<div>Abstract<p>The intestinal microbiome contributes to colorectal carcinogenesis, disease progression, and response therapy. Pathologic complete is the therapeutic goal of neoadjuvant chemoradiation in rectal carcinoma. Nonoperative management has become an accepted strategy, markers treatment are needed. Intestinal commensal bacteria contribute radiation colitis, microbiome-targeted therapies have shown promise clinical trials. We investigated relationship among...
<p>Table S2</p>